



NEW WITH AIRSTOP

PRESCRIPTION

PATIENT ACCESS

PREPARAT**I**ON

APPLICATION

DISCHARGE MANAGEMENT

Cyto-Set®

Advanced preparation and application of hazardous drugs

# Challenges in Chemotherapy

The treatment of chemotherapy is one of the most challenging processes within the infusion therapy. Starting with the preparation of the drug by way of transportation, administration to the patient and disposal after the treatment, healthcare workers, physicians, pharmacists and also the patients are permanently at the risk of endanger their health. International guidelines dictates the special handling of cytostatic drugs to reduce risks during the process. In line with the regulatory requirements Cyto-Set® is supporting the user to prevent the following risks:




### **Chemical Contamination**

Unintended exposure of a healthcare professional to hazardous drugs.

### Possible consequences

• Toxic contamination can lead both to acute symptoms (nausea, diarrhea, throat irritation, skin rashes, hair loss, even mutagenicity) or chronic symptoms (carcinogenicity, secondary malignant neoplasia due to the exposure to high doses of cytotoxic medication, reproductive effects). 1, 2



### Drug Incompatibility

• Undesirable reaction that occurs between the drug and a) the IV solution b) the container or c) another drug.

### Possible consequences<sup>3, 4, 5</sup>

- Damage from toxic drugs (e.g. dermatitis, antibiotics hypersensitivity)
- Particulate emboli from crystallization and separation (thrombophlebitis up to multi-organ failure)
- Tissue irritation due to major pH changes
- Therapeutic failure due to the reduction or elimination of the active drug



## **Microbiological Contamination**

- Infection which a patient incurs in a healthcare facility and which was not present at the time of admission. (incl. infections acquired in the hospital but appearing after discharge, and also occupational infections among the staff of the facility.)
- Infections are caused by microbiological pathogens like bacteria, viruses, prions or fungi, as well as by toxins and by-products that these pathogens release.

### Possible consequences

- Local infection consequences: surgical wound infections, skin irritations and catheter entry site infections
- Systemical inflammation consequences (pathogens reaching the systemic circulation): septicemia, sepsis and septic shock <sup>6, 7</sup>




### **Particulate Contamination**

• Unintended presence of extraneous, mobile and undissolved particles in a parenteral solution.

### Possible consequences

 Unfavorable effects (phlebitis, damage lungs<sup>8</sup>, kidneys, nodular fibrosis of the liver and spleen, granulomatous lung disease, myocarditis, occult pulmonary granulomas to local tissue infarction and pulmonary infarction)<sup>9</sup>



#### Medication Erro

• An error in prescribing, dispensing or administering of a drug, irrespective of whether such errors lead to adverse consequences or not.

### Possible consequences<sup>10</sup>

• Errors in IV drug preparation can have a broad range of consequences ranging from harmless to serious.



#### Sharp Injuries

Skin penetrating stab wounds caused by sharp instruments and accidents in a medical setting.
 These instruments include needles, lancets, scalpels and broken glass.

## Possible consequences

• The main concern regarding a needle stick injury (NSI) is not characterized by the trauma itself, but by the percutaneous exposure to a patient's blood and body fluids (BBF) which may carry infectious diseases. 11 The likelihood of developing a disease after a NSI depends on various independent factors: pathogen concentration in the blood and body fluids, depth of the wound, blood volume, amount of pathogens transmitted and the infection phase of the pathogen carrier.



### **DEHP-Exposure**

• Polyvinyl chloride (PVC) plastic is used to manufacture a huge number of articles for daily life, e.g. toys, building material such as flooring, cables, as well as medical products. Unplasticized PVC is hard and brittle at room temperature. As a result, plasticizers are necessary to impart flexibility to the polymer.

### Possible consequences

Health concerns about phthalate plasticizers are currently the subject of considerable media, legislative
and scientific debate. The exposure of human beings and especially developing children to DEHP can have
significant health consequences.<sup>12</sup>



### Air Embolism

• Vascular air embolism is the entrainment of air (or exogenously delivered gas) from the operative field or other communications with the environment into the venous or arterial vasculature, producing systemic effects.

### Possible consequences

- The symptons and clonical signs of air embolism are related to the degree of air entry into the circulation system. They usually develop immediately after embolization.<sup>13</sup>
- Air embolism can have a broad range of consequences ranging from harmless to serious.

# Risk Reduction with Cyto-Set®



The new and improved Cyto-Set® design is in line with our Safe Infusion Therapy concept to protect users and patients. In the field of drug preparation the wide spread portfolio of Cyto-Set® offers a high safety standard of each component. During the application on the ward the new Cyto-Set® portfolio not only improves handling but also increases the safety standard.

The variety of Cyto-Set® products is widespread and offers a convenient solution for the application of cytostatic drugs in several situations. When used together Cyto-Set® Mix, Cyto-Set® Infusion and Cyto-Set® Infusomat® Space provide a closed system from preparation in the pharmacy to the application on the ward, all the way to the disposal after the treatment.



Risk	Safety Feature	Safety Benefits
Chemical Contamination	<ul> <li>Needle-free valve</li> </ul>	<ul> <li>Helps to reduce the risk of chemical contamination as the valves are designed for preventing spillage/drug exposure.<sup>14</sup></li> </ul>
Microbiological Contamination	<ul> <li>Finger stopper and finger grip</li> </ul>	<ul> <li>Reduction of microbial contamination due to the finger stopper and finger grip.<sup>15</sup></li> </ul>
	<ul><li>PrimeStop</li></ul>	<ul> <li>Improved safety against microbial contamination due to the hydrophobic, bacteria retentive PrimeStop cap on the patient connector which provides a closed system until connection to the patient.<sup>16, 17</sup></li> </ul>
	<ul> <li>Needle-free valve</li> </ul>	<ul> <li>Provides easy access, while helping to reduce the chance of accidental touch contamination.<sup>18</sup></li> </ul>
	<ul> <li>Air vent filter in the spike</li> </ul>	• The bacteria tight air vent filter in the spike reduces the contamination risk of the infusion solution. 19
Drug Incompatibility	Grip plate with integrated back check valves	<ul> <li>Integrated back check valves enables an improved safety standard and less risk of unmeant mixture of drugs due to the prevention of reflux.<sup>20</sup></li> </ul>
Particulate Contamination	• 15 μm filter in the drip chamber	• A particle filter in the drip chamber with pore size of 15 $\mu$ m prevents the infusion of particles from the infusion container. <sup>21</sup>
	• 0.2 μm Sterifix® filter	$\bullet$ The 0.2 $\mu m$ Sterifix® filter retains bacteria, fungi, particles and air.
Sharps Injury	Needle-free valve	• Provides needle-free access, while eliminating the risk of needlestick injuries. 22, 23
Medication Error	Structure of the regime	• Due to the 90° angle of the valves in the grip plate, the whole Cyto-Set® regime is structured well, which reduces the risk of mistaking the drugs within the therapy.
Air Embolism	<ul><li>AirStop</li></ul>	AirStop function in drip chamber reduces the risk of air embolism. <sup>24</sup>
DEHP Exposure	PVC / DEHP free tubing	All lines are PVC-free, there is no risk of DEHP exposure.

# A Proven Closed System\*

### INNOVATION IN DESIGN AND TECHNOLOGY

Improved design of Cyto-Set® offers a higher level of patient and user safety due to it's new features. In addition to this, the features are supporting to increase the usability of the new portfolio due to the intuitive handling of the IV-Set.


As the precursor the new Cyto-Set® is a closed system\*, and the new portfolio has been tested according to NIOSH guidelines.\* No disconnection during the treatment or afterwards are necessary to dispose of the system.

### YOUR BENEFITS

- Cytostatic resistant material "Tritan™" is used for the needle-free valve to avoid the risk of chemical contamination caused by stress-cracking.
- Systematic arrangement of the needle-free valves supporting the user during application. This helps to reduce the risk of medication errors.
- Integrated back check valves to avoid drug incompatibilities and medication errors caused by unmeant reflux.
- Ergonmic design of grip plate and Y-site needle-free valve supports safe handling and helps to reduce risk of microbial contamination.
- Improved fluid flow leads to a reduced dead space volume of Y-site needle-free valve which is decreasing the risk of drug in compatibilities and air embolism.
- AirStop function in drip chamber prevents air entrainment into the infusion tubing and helps to reduce the risk of air embolism.



- \* Cyto-Set® is tested according to NIOSH guidelines as a closed system. Confirmation available
- \*\* Bacteria tightness of PrimeStop Cap. Confirmation available.
- \*\*\* Filter prevents the escape of any contamination into the adjacent environment. Confirmation available



# Drug Preparation in the Pharmacy



### Priming of Cyto-Set® Mix in the pharmacy

Protect yourself and your environment during the preparation of cytostatic drugs in the pharmacy by priming Cyto-Set® Mix first. As it is a matter of common knowledge cytostatic drugs can pose serious health harzards, Cyto-Set® Mix is supporting the pharmacists reducing the risk of contamination and helps to increase the process efficiency of admixing drugs.

Handling Step

Close venting cap.

## **Safety Feature**

Air vent filter in spike with integrated B.C.V. helps to avoid contamination during venting.

Handling Step

Spike the container.

### **Safety Feature**

Container stability of Ecoflac® plus allows easy and convenient spiking while helping to reduce risks of sharps injuries.

Handling Step

Prime the filter.

# **Safety Feature**

0.2 μm Sterifix® filters every particals larger than 0.2 μm to avoid particular contamination.

Handling Step
Prime the line completely.

### **Safety Feature**

Hydrophobic, bacteria retentive cap maintaining a closed system until connection to the main line without spillages of fluid.



### Drug preparation in the pharmacy with Cyto-Set® Mix

During the admixture process not only Cyto-Set® Mix but also a lot of supporting products of the widespread B. Braun portfolio is used. Besides proctective equipment (e.g. gloves) and disinfectiants, the closed male connector PureSite, the semi-rigid container Ecoflac® plus and the luer-lock syringe Omnifix® is used during the preparation process.

Handling Step

# Close white clamp close to the

## Safety Feature

needle-free valve.

Helps to avoid chemical contamination as only salin will remain at the connection site.

**→ ■ Handling Step**

Connect prepared syringe with diluted drug to the needle-free valve by using the finger plate.

### Safety Feature

Helping to reduce risk of microbiological contamination since no direct contact to the needle-free valve is needed. The needle-free valve is preventing needle-stick injuries.

**Handling Step** 


Inject drug into container and mix the high concentrated drug well by aspirating once or twice.

## Safety Feature

Drug is administered in accordance with the prescripted concentration.

PRESCRIPTION PATIENT ACCESS PREPARATION APPLICATION DISCHARGE MANAGEMENT

# Application on the Ward



### Priming of Cyto-Set® main line on the ward

Cyto-Set® main line is designed for a safe drug application on the ward while supporting the idea of a safe procedure of handling before, during and after the treatment. Cyto-Set® is supporting the process with features dedicated to the environment of an oncology ward.

Handling Step

Close venting cap.

### **Safety Feature**

Air vent filter in spike with integrated B.C.V. to avoid contamination during venting.

Handling Step

Spike the container.

### **Safety Feature**

Tight connection. Once inserted the spike stays firmly connected to reduce the chance of being disconnected accidentaly.

Handling Step

While allowing system to fill, hold the drip chamber upside down.

### **Safety Feature**

Fluid filter in the drip chamber to avoid particular contamination.

Handling Step
Prime the line completely.

### **Safety Feature**

Hydrophobic, bacteria retentive cap maintaining a closed system until connection to the main line without spillages of fluid.



### Drug application on the ward with Cyto-Set® & Cyto-Set® Mix

The fact that the numbers of cytostatic drugs available on the market increase and the prices for most of the drugs are stable on a high level any residual volume in the IV-Set as well as drug incompatibilities increases the risk of an uneffective treatment or of an unefficient process. The concept of Cyto-Set® is supporting the process by helping to increase: efficiency, effectiveness and safety!

Handling Step

Close white clamp of main line.

### Safety Feature

Closed clamp prevents a contamination of flushing solution to reduce the risk of drug incompatibilites.

Handling Step


Connect Cyto-Set® Mix to main line, open white clamp and start treatment.

### Safety Feature

A tactile "click" will let the user know that the sets are connected.

PRESCRIPTION PATIENT ACCESS PREPARATION APPLICATION DISCHARGE MANAGEMENT

# Application on the Ward and Disposal



# Drug application on the ward with Cyto-Set® & Cyto-Set® Mix

In order to support the cancer treatment Cyto-Set® is enabling the user to flush the IV-Set after the treatment completely for the application of the whole medication in accordance with the prescription.

# Handling Step

After each drug flush the line completely with flushing solution.

### **Safety Feature**

The full amount of drug is given to the patient which helps to reduce the risk of medication errors.

Thanks to AirStop function the fluid level remains in the drip chamber after drug application. The line is not running dry which helps to prevent air embolism.

# → Handling Step

Open clamp of next Cyto-Set® Mix to start the next treatment.

### Safety Feature

Flushing plus integrated back check valves helps to reduce the risk of drug incompatibilities.



### Disposal as a complete system

Even after the treatment the IV-Set and the contaminated containers need the undivided attention to protect the user and the environment. The whole Cyto-Set® portoflio is also supporting the healthcare worker afterwards to dispose the system in a convenient way.

■ Handling Step

Dispose as a closed system.

### Safety Feature

Helps to avoid the risk of chemical contamination because no disconnection is necessary.

PRESCRIPTION PATIENT ACCESS PREPARATION APPLICATION DISCHARGE MANAGEMENT

# **Product Portfolio**

Cyto-Set®	Product	Туре	Light	AirStop	Units	Code no.	
			protection		per box	(REF)	
	Preparation						
	Cyto-Set® Mix	with 1 needle-free valve				A2900N	
		with 1 needle-free valve,	_	_		A2903N	
		with 0.2 μm filter					
1		with 1 needle-free valve			20	A2906N	
	Cyto-Set® Line	without needle-free valve				A2581NF	
		without needle-free valve,	_	_		A2582NF	
	A 11 11 (0 11	with 0.2 μm filter					
No.	Application (Gravity					4.005	
		with 3 needle-free valves				A1687	
A STATE OF THE STA	Cyto-Set® Infusion	with 5 needle-free valves			20	A1686SNF	
		with 3 needle-free valves				A1688	
		with 5 needle-free valves	-	•		A1687SNF	
	Application (Pump)	Infusomat® Space					
	Cyto-Set® Infusomat® Space	with 3 needle-free valves	-	-	20	8250917SP	
		with 3 needle-free valves	_	•		835917SP	
		with 5 needle-free valves	_	_		8250817SP	
		with 5 needle-free valves	-	•		835817SP	
		with 3 needle-free valves	•	_		8250920SP	
		with 3 needle-free valves		•		835920SP	
		with 5 needle-free valves		_		8250820SP	
		with 5 needle-free valves	•	•		835820SP	
		with 5 needle-free valves,				8250414SP	
		with 0.2 μm filter				023041431	
		with 5 needle-free valves,	_	•		835414SP	
		with 0.2 μm filter					
	Cyto-Set® Pump Adapter	4 needle-free valves				A1673S0	

# Product Portfolio & Literature

Cyto-Set®	Product	Туре	Light protection	AirStop	Units per box	Code no. (REF)		
	Application (Pump) Infusomat® compact <sup>plus</sup>							
	Cyto-Set <sup>®</sup> Infusomat <sup>® plus</sup>	with 3 needle-free valves	_	_		8700480		
		with 3 needle-free valves	-	•	20	8700420		
The same		with 5 needle-free valves	_	_		8700490		
		with 5 needle-free valves	_	•		8700430		
		with 3 needle-free valves		•		8700440		
		with 5 needle-free valves	•	•		8700450		
		with 5 needle-free valves, with 0.2 µm filter	_	_		8700470		
		with 5 needle-free valves, with 0.2 μm filter	-	-		8700460		

### Literature

- McDiarmid MA, Egan T. Acute occupational exposure to antineoplastic agents. J Occup Med 1988; 30(12): 984–987
- Valanis GB, Vollmer WM, Labuhn KT, Glass AG. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm 1993b; 50; 455-462
- Fahimi F, Sefidani Forough A, Taghikhani S, Saliminejad L (2015) The rate of Physicochemical Incompatibilities, Administration Errors. Factors correlating with Nurses' errors. Iran J Pharm Res; 14(suppl); 87–93
- Vijayakumar A, Sharon EV, Teena J, Nobil S, Nazeer I. (2014) A clinical study on drug-related problems associated with intravenous drug administration. J Basic Clin Pharm; 5(2): 49–53
- Höpner JH, Schulte A, Thiessen J, Knuf M, Huth RG. (2007) Preparation of a compatibility chart for intravenous drug therapy in neonatal and pediatric intensive care units. Klin Padiatr; 219(1): 37-43
- Uslusoy E., Mete S.: Predisposing factors to phlebitis in patients with peripheral intravenous catheters: a descriptive study. J Am Acad Nurse Pract. 2008; 20(4): 172-80
- Bouchoucha et al. Deep venous thrombosis associated with acute hematogenous osteomyelitis in children. Orthop Traumatol Surg Res. 2010 Dec; 96(8): 890-3., Boucher 2010
- Dewan et al. 1995b; publications ex Dewan et al. 2002; Ewan PA, Stefanek W, Byard RW.
   Long-term response to intravenously injected Teflon and Silicone in a rat model. Pediatric
   Surgery Interantional 1995b; 10(2,3): 129-133
- Roth 2007, Lehr et al. 2002; Roth JV. How to enter a medication vial without coring. Anesth Analg 2007; 104(6): 1615
- Cousins DH, Sabatier B, Begue D, Schmitt C, Hoppe-Tichy T (2005) Medication errors in intravenous drug preparation and administration: a multicentre audit in the UK, Germany and France. OSHC 14: 190-195
- Canadian Center for Occupational Health and Safety (CCOHS); Needlestick injuries. 2000. (www.ccohs.ca/oshanswers/diseases/needlestick\_injuries.html)
- National toxicology programm, the US department of health and human services
   (11/2006) HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/?term=NTP-CERHR+Mono graph+on+the+Potential+Human+Reproductive+and+Developmental+Effects+of+Di
   (2-Ethylhexyl)"Center for the evaluation of risks to human reproduction: NTP-CERHR Mono graph on the Potential Human Reproductive and Developmental Effects of Di(2-Ethylhexyl)
   Phthalate (DEHP). NIH Publication No. 06 4476.

- 13. Mirski et al. 2007 Wittenberg 2006, Josephson 2006, Perdue 2001
- Abstract Closed system test by means of Sodium Fluorescein signed by Dr. rer. nat. J. Brünke Quality Labs BT GmbH Nuremberg, Report 1816.3, 01.09.2015
- Abstract Evaluation of the microbial barrier performance of Cyto-Set® and Cyto-Set® Mix (NEW) signed by Prof. Dr. med. M.Exner and Dr. rer. nat. J. Gebel, Report DMT 2014–195, 23 02 2015
- Test Report Closed system test by means of Sodium Fluorescein signed by Dr. rer. nat. J. Brünke Quality Labs BT GmbH Nuremberg, Report 1678.3, 28.05.2013
- $17. \ \ Confirmation \ PrimeStop \ Cap-Bacteria \ tightness \ of \ PrimeStop \ Cap. \ Confirmation \ available.$
- Abstract Evaluation of the microbial barrier performance of Cyto-Set® and Cyto-Set® Mix (NEW) signed by Prof. Dr. med. M.Exner and Dr. rer. nat. J. Gebel, Report DMT 2014–195, 23.02.2015
- Confirmation Air vent filter Filter prevents the escape of any contamination into the adjacent environment signed by Andreas Katerkamp and Dr. Stefan Seidel, 01.11.2016
- Non-return valves do not prevent backflow and bacterial contamination of intravenous infusions written by B. Ellger, D. Kiski, E. Diem, I. van den Heuvel, H. Freise, H. Van Aken, F. Hinder, A. W. Friedrich, 11.03.2011, Journal of Hospital Infection
- Confirmation ISO Standard ISO 8536-4 signed by Gudrun Henke and Caroline Führ, 01.02.2017
- American Nurses Association Independent Study Module: Needlestick Safety and Prevention written by Mary Foley, MS, RN and Annemarie T. Leyden, EdD, RN
- Review Article Review on Needle Free Drug Delivery Systems, International Journal of Pharma Research & Review, written by Bhagyashri Chavan, Abha Doshi, Yashwant Malode, Balu Misal, Sept 2013; 2(9):30–36
- Pheriphervenöse Schwerkraftinfusionen Intrafix® SafeSet mit Vorteilen gegenüber herkömmlichen Infusionssystemen written by lic. rer. pol. Andreas Frei, Die Schwester Der Pfleger 43. Jahrg. 5/04





For further information about Risk Prevention in Infusion Therapy, please refer to the Risk Prevention brochures or scan the  $\Omega R$ -code and visit:

WWW.SAFEINFUSIONTHERAPY.COM

B. Braun Melsungen AG | Hospital Care | 34209 Melsungen | Germany Tel. +49 5661 71-0 | www.bbraun.com